Chemotherapy-induced nausea and vomiting in children – the missing evidence
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Chemotherapy-induced nausea and vomiting in children – the missing evidence. / Eliasen, Astrid; Schmiegelow, Kjeld; Rechnitzer, Catherine; Brok, Jesper; Dalhoff, Kim; Mathiasen, René.
I: Adverse Drug Reaction Bulletin, Bind 328, Nr. 1, 2021, s. 1271-1274.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Chemotherapy-induced nausea and vomiting in children – the missing evidence
AU - Eliasen, Astrid
AU - Schmiegelow, Kjeld
AU - Rechnitzer, Catherine
AU - Brok, Jesper
AU - Dalhoff, Kim
AU - Mathiasen, René
PY - 2021
Y1 - 2021
N2 - hemotherapy-induced nausea and vomiting (CINV) is a devastating adverse effect associated with treatment of childhood cancer that can lead to disruption of normal childhood activities and delay in important treatment with oral medicaments. Guidelines have been developed by several cancer associations helping clinicians to select proper antiemetic prophylaxis.1–4 Generally, 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists, neurokinin 1 (NK1) receptor antagonists, and dexamethasone are recommended to prevent CINV in children. The evidence directing these guidelines is limited by lack of available paediatric studies, and CINV control remains therefore often suboptimal for patients and a clinical challenge for healthcare professionals. However, emerging paediatric data are available in this increasingly popular research area, and newer antiemetic drugs, including olanzapine and lorazepam, may improve the CINV control.In this review, we provide information on the missing evidence in prevention and treatment of CINV in children, discuss barriers to use the available guidelines, and highlight areas for further research.
AB - hemotherapy-induced nausea and vomiting (CINV) is a devastating adverse effect associated with treatment of childhood cancer that can lead to disruption of normal childhood activities and delay in important treatment with oral medicaments. Guidelines have been developed by several cancer associations helping clinicians to select proper antiemetic prophylaxis.1–4 Generally, 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists, neurokinin 1 (NK1) receptor antagonists, and dexamethasone are recommended to prevent CINV in children. The evidence directing these guidelines is limited by lack of available paediatric studies, and CINV control remains therefore often suboptimal for patients and a clinical challenge for healthcare professionals. However, emerging paediatric data are available in this increasingly popular research area, and newer antiemetic drugs, including olanzapine and lorazepam, may improve the CINV control.In this review, we provide information on the missing evidence in prevention and treatment of CINV in children, discuss barriers to use the available guidelines, and highlight areas for further research.
U2 - 10.1097/FAD.0000000000000055
DO - 10.1097/FAD.0000000000000055
M3 - Review
VL - 328
SP - 1271
EP - 1274
JO - Adverse Drug Reaction Bulletin
JF - Adverse Drug Reaction Bulletin
SN - 0044-6394
IS - 1
ER -
ID: 302073088